Minnesota surpassed $250 million in cannabis sales during its first full year of statewide licensed retail, while cultivation capacity and social equity participation expanded rapidly. The next test is whether rising supply can improve product availability without putting unsustainable pressure on smaller operators and margins.

A Pennsylvania performance audit found weaknesses in medical cannabis inspections, complaint handling, enforcement documentation, and corrective action oversight. The findings could lead to more standardized regulatory reviews and make strong operator records, SOPs, training, and internal compliance systems increasingly important.

Maine is distributing 12,000 free lockable cannabis storage bags through retailers, caregivers, and public health partners as part of its Safe Storage for ME initiative. The expanded program gives licensed businesses a direct role in consumer education, child safety, responsible storage, and community trust.

The United States has one of the world's largest cannabis markets but remains a minor participant in international medical cannabis trade. Federal medical rescheduling could create new opportunities, but U.S. operators still face established foreign competitors, pharmaceutical quality standards, permitting requirements, logistics costs, and growing domestic production in importing markets.

DEA has released the complete 2,533 page transcript from 11 days of federal cannabis rescheduling hearings as the administrative law judge prepares a recommendation. The record moves the process closer to a decision while operators continue facing uncertainty around 280E, federal compliance, medical cannabis strategy, research, and investment timing.

Canada remains the world's largest medical cannabis exporter, but growing European production is beginning to challenge its lead. Germany's expanding market, Portugal's rapid export growth, stricter pharmaceutical standards, reimbursement changes, and new lower cost suppliers are reshaping international cannabis competition.

Canada still supplies most of Australia's imported medical cannabis, but Thailand rapidly gained market share in 2025 while Australian domestic production reached a new high. The shift shows an increasingly competitive supply chain where pricing, quality standards, contracts, inventory, and reliable international market access matter more.

South Dakota medical cannabis home cultivation has increased more than 1,000 percent in four years, rising from 61 authorized patients to 715. The surge highlights growing pressure around affordability, patient access, dispensary strategy, cultivation oversight, and the balance between personal cultivation and the regulated commercial market.

Georgia is considering allowing licensed dispensaries to mail medical cannabis directly to registered patients within the state following new federal Schedule III treatment. The proposal could expand patient access dramatically, but operators still need clarity around DEA requirements, postal rules, carrier acceptance, tracking, security, and patient verification.

Illinois adult use dispensaries will be able to opt into medical cannabis licensing beginning September 10, opening new opportunities around patient access, retail sales, DEA registration, and federal tax planning. The bigger lesson is that cannabis license structure is becoming increasingly important as state medical programs interact with new federal Schedule III rules.